Compounding pharmacies create customized medications tailored to individual patient needs, filling a critical gap where commercial drug formulations are unavailable, inappropriate, or unaffordable. The industry operates under a dual regulatory framework involving state pharmacy boards and increasing FDA oversight, particularly for sterile preparations, creating meaningful barriers to entry. Demand is driven by aging demographics, growth in hormone replacement therapy, veterinary medicine, and specialty pain management, making the sector both resilient and attractive to healthcare-focused acquirers.
Who buys these: Licensed pharmacists seeking ownership, private equity groups targeting specialty healthcare, strategic acquirers such as pharmacy chains or healthcare networks, and entrepreneurial investors with pharmacy or healthcare operations backgrounds
3.5–6×
Typical EBITDA multiple
$1M–$5M
Revenue range
Growing
Market trend
SBA Eligible
7(a) financing available
Recession Resistant
Essential service
Browse Compounding Pharmacy Businesses for Sale →
Search live acquisition targets near you — pre-filtered to Compounding Pharmacy
Minimum $500K SDE or $1M+ revenue; licensed and accredited facility (PCAB preferred); clean regulatory history with no FDA 483 observations; diversified prescriber base; documented SOPs for compounding processes; buyer must hold or obtain pharmacist-in-charge licensure
Get Deal Flow In Your Inbox
New Compounding Pharmacy acquisition targets delivered weekly — free to join.
Key items to investigate when evaluating a Compounding Pharmacy acquisition
What buyers typically pay for Compounding Pharmacy businesses
3.5×
Low Multiple
4.8×
Mid Multiple
6×
High Multiple
Compounding Pharmacy businesses in the $1M–$5M revenue range trade at 3.5–6× EBITDA in the lower middle market. Multiple variance is driven by recurring revenue percentage, owner dependency, client concentration, and growth trajectory. Growing market conditions support multiples at or above the midpoint.
Full valuation guide for Compounding PharmacyCompounding Pharmacy acquisitions are SBA 7(a) eligible, meaning buyers can finance up to 90% of the purchase price. This expands the qualified buyer pool significantly and allows first-time acquirers to close with 10% down. Typical SBA terms run 10 years at prime + 2.75%. Sellers are often asked to carry a 5–10% note alongside SBA financing to satisfy the lender's equity requirement.
Typical acquirer profile for this segment
Licensed pharmacists with ownership aspirations backed by SBA financing, strategic acquirers such as specialty pharmacy groups or health systems seeking to expand compounding capabilities, and private equity-backed healthcare platforms pursuing add-on acquisitions
What to investigate before buying a Compounding Pharmacy business
Seller Intelligence
Who sells Compounding Pharmacy businesses?
Pharmacist-owners approaching retirement, founders seeking liquidity after building a niche compounding practice, owners facing regulatory fatigue or capital constraints for facility upgrades, and multi-location pharmacy operators looking to divest a single compounding unit
Typical exit timeline: 12–24 months
Compounding Pharmacy businesses in the $1M–$5M revenue range typically sell for 3.5–6× EBITDA. Minimum $500K SDE or $1M+ revenue; licensed and accredited facility (PCAB preferred); clean regulatory history with no FDA 483 observations; diversified prescriber base; documented SOPs for compounding processes; buyer must hold or obtain pharmacist-in-charge licensure
Compounding Pharmacy businesses typically trade at 3.5–6× EBITDA in the lower middle market. The market is highly fragmented with growing demand, which supports premium multiples.
Compounding Pharmacy businesses are SBA 7(a) eligible, making them accessible to first-time buyers. Full asset acquisition with SBA 7(a) financing, seller note of 10–15%, and earnout tied to prescriber retention
Key due diligence areas include: State pharmacy board license status and history of any disciplinary actions or warnings; USP 795, 797, and 800 compliance documentation including beyond-use dating policies and cleanroom certifications; Prescriber referral concentration and transferability of key physician relationships; Revenue mix between sterile and non-sterile formulations and top compound categories; Payer mix analysis including cash-pay vs. insurance reimbursement and any third-party audit exposure.
More Compounding Pharmacy Guides
How to Buy a Pharmacy: The Complete Acquisition Guide
Independent pharmacies trade at 3–6x EBITDA with strong prescription revenue and motivated aging-owner sellers. Here's how to evaluate, finance, and close a pharmacy acquisition.
Independent vs. Chain Pharmacy Valuation: 2026 Guide
How independent and chain pharmacy valuations differ in 2026: script count benchmarks, DIR fee impact, 340B program, front-end revenue mix, and what buyers pay for each.
Pharmacy Acquisition Multiples in 2026: EBITDA & Revenue
2026 pharmacy acquisition multiples: 0.5x–1.5x revenue or 3x–6x EBITDA, PBM risk, script count benchmarks, DEA transfer, 340B eligibility, and what drives premium pricing.
Related Searches
DealFlow OS surfaces acquisition targets, scores seller motivation, and generates outreach — all in one place.
Start finding deals — freeNo credit card required
For Buyers
For Sellers